Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Tops BioPharm Insight Global Licensing Agreements

February 9, 2010

LONDON, February 9, 2010BioPharm Insight has ranked Covington & Burling LLP as the top legal advisor for biotech and pharma licensing agreements by value. Along with leading the 2009 league tables by value globally and in North America, Covington was ranked first by volume and second by value in Europe, and in Asia, the firm topped both the value and volume tables.

Covington also placed in BioPharm Insight’s top 20 list for global and North American mergers and acquisitions, advising on deals valued at nearly $50 billion, including the merger of Merck and Schering-Plough.

BioPharm Insight provides detailed research and information on all stages of global drug development activities in the biotech and pharmaceutical industries. Its league tables are based on drug licensing agreements announced between 1 January to 31 December, and the dominant geography of either target, bidder or seller.

Covington’s life sciences practice is widely recognized for excellence, and has been ranked in Chambers Global, Chambers USA, Chambers UK, Legal 500 USA, Legal 500 UK and Legal 500 EMEA. In 2009, Covington was ranked the number one life sciences law firm in the world for the fourth consecutive year, as well as the number one life sciences regulatory practice for the sixth year running by Practical Law Company.

Share this article: